var data={"title":"Toxoplasmosis in HIV-infected patients","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Toxoplasmosis in HIV-infected patients</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Rajesh T Gandhi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">John G Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 21, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Toxoplasmosis is the most common central nervous system infection in patients with the acquired immunodeficiency syndrome (AIDS) who are <strong>not</strong> receiving appropriate prophylaxis [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/1,2\" class=\"abstract_t\">1,2</a>]. This infection has a worldwide distribution and is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>. Immunocompetent persons with primary toxoplasmosis are usually asymptomatic, and latent infection can persist for the life of the host. In immunosuppressed patients, especially patients with AIDS, the parasite can reactivate and cause disease, usually when the CD4 count falls below 100 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/1,3,4\" class=\"abstract_t\">1,3,4</a>].</p><p>This topic will focus on the clinical manifestations, diagnosis, and treatment of toxoplasmosis in HIV-infected patients. A discussion of toxoplasmosis in immunocompetent hosts is found elsewhere. (See <a href=\"topic.htm?path=toxoplasmosis-in-immunocompetent-hosts\" class=\"medical medical_review\">&quot;Toxoplasmosis in immunocompetent hosts&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The probability of developing reactivated toxoplasmosis is as high as 30 percent among AIDS patients with a CD4 count &lt;100 <span class=\"nowrap\">cells/microL</span> who are toxoplasma seropositive and are not receiving effective prophylaxis or antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/5-8\" class=\"abstract_t\">5-8</a>]. The most common site of reactivation is the central nervous system (CNS). </p><p class=\"headingAnchor\" id=\"H878458677\"><span class=\"h2\">Transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In humans, toxoplasmosis is typically acquired through ingestion of infectious oocysts, usually from soil or cat litter contaminated with feline feces, or undercooked meat from an infected animal. When humans ingest <em>T. gondii</em> oocysts, the organisms invade the intestinal epithelium and disseminate throughout the body. They then encyst in any type of nucleated cell and can lie dormant within tissues for the life of the host. A more detailed discussion on the transmission of toxoplasmosis is found elsewhere. (See <a href=\"topic.htm?path=toxoplasmosis-in-immunocompetent-hosts\" class=\"medical medical_review\">&quot;Toxoplasmosis in immunocompetent hosts&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Prevalence of infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of infection with <em>T. gondii</em> varies substantially among different countries and ranges from approximately 11 percent in the United States to more than 80 percent in certain European, Latin American, and African countries [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. In general, the seroprevalence of antibodies to <em>T. gondii</em> among HIV-infected patients mirrors the rate of seropositivity in the general population and is not related to owning a cat [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/10,11\" class=\"abstract_t\">10,11</a>]. However, the prevalence may be associated with age. As an example, in a study of HIV-infected women in the United States, those who were &ge;50 years old were more likely to be seropositive compared with younger women (odds ratio 2.4, 95% CI 1.4 to 3.9) [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Prior to the introduction of potent antiretroviral therapy (ART), the incidence of toxoplasmic encephalitis (TE) in AIDS patients reflected the seropositivity rates in this population [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/12\" class=\"abstract_t\">12</a>]. However, the widespread use of ART has decreased the incidence of TE. As an example, among HIV-infected patients in the United States, the annual number of toxoplasmosis-related hospitalizations peaked at more than 10,000 in 1995, dropped sharply to 3643 in 2001, and then decreased to 2985 in 2008 [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=the-natural-history-and-clinical-features-of-hiv-infection-in-adults-and-adolescents\" class=\"medical medical_review\">&quot;The natural history and clinical features of HIV infection in adults and adolescents&quot;</a>.)</p><p>Extracerebral toxoplasmosis is much less common than CNS disease. This was illustrated in a series of 1699 HIV-infected patients from France, of whom 116 had confirmed, probable, or possible toxoplasmosis [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/14\" class=\"abstract_t\">14</a>]. Cerebral toxoplasmosis was identified in 89 percent of patients, with pulmonary, ocular, and disseminated infection responsible for 6, 3.5, and 1.7 percent of cases, respectively. </p><p>The most prominent risk factor for the development of extracerebral toxoplasmosis is advanced immunosuppression (eg, CD4 count &lt;100 <span class=\"nowrap\">cells/microL)</span> [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/14,15\" class=\"abstract_t\">14,15</a>]. In addition, concurrent CNS disease is often seen. In one series of 199 patients with extracerebral toxoplasmosis, CNS disease was also present in 41 percent of patients [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactivation of toxoplasmosis most frequently presents with signs and symptoms of central nervous system disease in HIV-infected patients with a CD4 count &lt;100 <span class=\"nowrap\">cells/microL</span>. (See <a href=\"#H7\" class=\"local\">'Toxoplasmic encephalitis'</a> below.)</p><p>Extracerebral disease can also occur, and may be present at more than one site [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"#H8\" class=\"local\">'Extracerebral toxoplasmosis'</a> below.)</p><p>There are no routine laboratory findings that are specific for toxoplasmosis. However, the LDH can be markedly increased in patients with disseminated toxoplasmosis and pulmonary disease [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Evaluation of cerebrospinal fluid (CSF) typically reveals a mild mononuclear pleocytosis and an elevated protein.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Toxoplasmic encephalitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with toxoplasmic encephalitis typically present with headache <span class=\"nowrap\">and/or</span> other neurologic symptoms. Fever is usually, but not reliably, present. As an example, in a retrospective review of 115 cases, 55, 52, and 47 percent had headache, confusion, and fever, respectively [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/1\" class=\"abstract_t\">1</a>]. Focal neurologic deficits or seizures are also common. Mental status changes range from dull affect to stupor and coma and can result from global encephalitis <span class=\"nowrap\">and/or</span> increased intracranial pressure. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Extracerebral toxoplasmosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary and ocular findings are the most common extracerebral manifestations, although disseminated disease can also occur.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Pneumonitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Toxoplasmic pneumonitis presents with fever, dyspnea, and a non-productive cough [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/18\" class=\"abstract_t\">18</a>]. Chest radiographs typically have reticulonodular infiltrates. The clinical picture may be indistinguishable from <em>Pneumocystis jirovecii</em> (formerly <em>carinii</em>) pneumonia (ie, PCP). (See <a href=\"topic.htm?path=toxoplasma-pneumonia-and-other-parasitic-pulmonary-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Toxoplasma pneumonia and other parasitic pulmonary infections in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Chorioretinitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with toxoplasmic chorioretinitis (a posterior uveitis) usually present with eye pain and decreased visual acuity. Toxoplasmic chorioretinitis appears as raised, yellow-white cottony lesions in a non-vascular distribution (unlike the perivascular exudates of CMV retinitis). Chorioretinitis due to <em>T. gondii</em> can rarely mimic acute retinal necrosis [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/19\" class=\"abstract_t\">19</a>]. </p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Other manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Toxoplasmosis can rarely present at a variety of other sites, including the gastrointestinal tract, liver, musculoskeletal system, heart, bone marrow, bladder, spinal cord, and testes [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/15,20,21\" class=\"abstract_t\">15,20,21</a>]. Disseminated disease presenting with septic shock has also been reported and can result from reactivation disease or primary infection [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/22\" class=\"abstract_t\">22</a>]. In some cases, involvement of the organ system may only be appreciated on autopsy [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Approach to diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the majority of patients, therapy is initiated after making a presumptive, rather than definitive, diagnosis of toxoplasmic encephalitis (TE). (See <a href=\"#H21\" class=\"local\">'Treatment'</a> below.)</p><p>A definitive diagnosis of TE requires a compatible clinical syndrome (eg, headache, neurological symptoms, fever), identification of one or more mass lesions by brain imaging, and detection of the organism in a biopsy specimen [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. However, for most patients presenting with central nervous system (CNS) disease, a presumptive diagnosis of TE is made in order to avoid a brain biopsy, given the associated morbidity and mortality of the procedure. (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions#H19\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;, section on 'Brain biopsy'</a>.)</p><p>A presumptive diagnosis can be made if the patient has a CD4 count &lt;100 <span class=\"nowrap\">cells/microL,</span> has not been receiving effective prophylaxis to prevent toxoplasmosis (see <a href=\"#H30\" class=\"local\">'Primary prophylaxis'</a> below), and has all of the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A compatible clinical syndrome (see <a href=\"#H7\" class=\"local\">'Toxoplasmic encephalitis'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A positive <em>T. gondii</em> IgG antibody (see <a href=\"#H14\" class=\"local\">'Serology'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brain imaging (preferably magnetic resonance imaging) that demonstrates a typical radiographic appearance (eg, multiple ring-enhancing lesions) (see <a href=\"#H15\" class=\"local\">'Imaging'</a> below)</p><p/><p>If these criteria are present, there is a 90 percent probability that the diagnosis is TE [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/4,24\" class=\"abstract_t\">4,24</a>]. For patients who can safely undergo lumbar puncture, analysis of cerebrospinal fluid (CSF) should also be performed to evaluate for evidence of <em>T. gondii</em>, as well as other infectious and non-infectious causes of CNS lesions. If toxoplasmosis is identified using polymerase chain reaction (PCR), the diagnosis of TE is even more likely (see <a href=\"#H878459301\" class=\"local\">'Polymerase chain reaction'</a> below). A detailed discussion on the evaluation of HIV-infected individuals with CNS lesions is found elsewhere. (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p>An alternative diagnosis becomes more likely if all of the above criteria are <strong>not</strong> met, CSF evaluation reveals an alternative diagnosis, <strong>or</strong> the patient has not responded to initial therapy (see <a href=\"#H26\" class=\"local\">'Response to therapy'</a> below). In such cases, other diagnostic tests <span class=\"nowrap\">and/or</span> brain biopsy should be performed. As an example, if a solitary CNS lesion is detected, even if toxoplasma serology is positive, then evaluation for CNS lymphoma should be performed [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/25\" class=\"abstract_t\">25</a>]. Which tests to order depends upon the clinical presentation. (See <a href=\"#H20\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Establishing a diagnosis of extracerebral toxoplasmosis also depends upon the clinical presentation. For those with pulmonary disease, demonstration of tachyzoites in tissue or fluid (eg, bronchoalveolar lavage) is usually required (see <a href=\"topic.htm?path=approach-to-the-hiv-infected-patient-with-pulmonary-symptoms\" class=\"medical medical_review\">&quot;Approach to the HIV-infected patient with pulmonary symptoms&quot;</a>). For those with ocular manifestations, the diagnosis is made based upon clinical findings consistent with toxoplasmosis. (See <a href=\"#H10\" class=\"local\">'Chorioretinitis'</a> above.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Serology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The vast majority of patients with TE are seropositive for anti-toxoplasma IgG antibodies [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/26\" class=\"abstract_t\">26</a>]. The absence of antibodies to toxoplasma makes the diagnosis less likely, but does not completely exclude the possibility of TE [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. Anti-toxoplasma IgM antibodies are usually absent and quantitative IgG antibody titers are not helpful. </p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Magnetic resonance imaging (MRI), if available, is the imaging modality of choice for evaluating patients with possible TE. Most AIDS patients with TE have multiple ring-enhancing brain lesions, often associated with edema. In a report of 45 patients with TE who underwent computed tomography (CT) or MRI, for example, 31 (69 percent) had multiple lesions and 14 had single lesions [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/27\" class=\"abstract_t\">27</a>]. There is a predilection for involvement of the basal ganglia [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/20\" class=\"abstract_t\">20</a>]. </p><p>MRI is more sensitive than CT for identifying the lesions associated with TE [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/28,29\" class=\"abstract_t\">28,29</a>]. This was illustrated in a prospective study of 50 patients with AIDS and neurologic symptoms that compared MRI and CT for the evaluation of TE [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/28\" class=\"abstract_t\">28</a>]. The MRI influenced the diagnosis and treatment of 20 patients (40 percent) whose lesions were not characterized by CT. However, neither CT nor MRI can adequately distinguish toxoplasmosis from other CNS lesions (eg, CNS lymphoma, cryptococcoma). A discussion on the differential diagnosis of HIV-infected patients presenting with CNS lesions is found elsewhere. (See <a href=\"#H20\" class=\"local\">'Differential diagnosis'</a> below and <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H45189708\"><span class=\"h2\">Occasionally performed tests</span></p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Nuclear imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thallium single photon emission computed tomography (SPECT) and positron emission tomography (PET) can be useful in distinguishing CNS lymphoma from TE or other infections. Lymphoma has greater thallium uptake on SPECT, and greater glucose and methionine metabolism on PET, compared with TE or other infections [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/30-32\" class=\"abstract_t\">30-32</a>]. This imaging modality is particularly useful for patients with solitary lesions who are poor candidates for brain biopsy [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/33,34\" class=\"abstract_t\">33,34</a>]. </p><p class=\"headingAnchor\" id=\"H824493468\"><span class=\"h3\">Visualization of the organism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A definitive diagnosis of TE is made by visualization of organisms on brain tissue obtained by open or stereotactic brain biopsy. Organisms are typically demonstrated on hematoxylin and eosin stains; however, immunoperoxidase staining may increase the diagnostic sensitivity [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/35\" class=\"abstract_t\">35</a>]. Tachyzoites can also been seen in fluid specimens including cytocentrifuged cerebrospinal fluid samples and bronchoalveolar lavage. The sensitivity of brain biopsy is as high as 93 percent [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/36\" class=\"abstract_t\">36</a>]. </p><p class=\"headingAnchor\" id=\"H878459301\"><span class=\"h3\">Polymerase chain reaction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Detection of <em>T. gondii</em> by PCR in cerebrospinal fluid has demonstrated high specificity (96 to 100 percent), but variable sensitivity (50 to 98 percent), depending upon the primers used [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/37-39\" class=\"abstract_t\">37-39</a>]. Treatment also affects diagnostic sensitivity. Thus, a positive PCR result establishes the diagnosis of TE, but a negative one does not rule it out.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H382302669\"><span class=\"h2\">Central nervous system disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of toxoplasmic encephalitis (TE) includes central nervous system (CNS) lymphoma, mycobacterial infection, cryptococcosis, bacterial abscess, and uncommonly, progressive multifocal leukoencephalopathy. Testing of cerebrospinal fluid for pathogens associated with these conditions (eg, Epstein-Barr virus [EBV], JC virus, <em>Mycobacterium tuberculosis</em>, <em>Cryptococcus neoformans</em>) can be used to help identify these alternative causes of infection [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/36\" class=\"abstract_t\">36</a>]. A detailed discussion on the evaluation of HIV-infected patients with central nervous system lesions is found elsewhere (<a href=\"image.htm?imageKey=ID%2F50593\" class=\"graphic graphic_algorithm graphicRef50593 \">algorithm 1</a>). (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.) </p><p><strong>Extracerebral disease</strong> &mdash; For patients with extracerebral toxoplasmosis, the differential depends upon the organ system involved. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of pulmonary symptoms in HIV-infected individuals is broad and can include bacterial, viral, mycobacterial, and fungal pathogens. A discussion on the differential diagnosis of HIV-infected individuals with pulmonary symptoms and the approach to diagnosis are discussed separately. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients#H115377349\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients&quot;, section on 'Differential diagnosis'</a> and <a href=\"topic.htm?path=approach-to-the-hiv-infected-patient-with-pulmonary-symptoms\" class=\"medical medical_review\">&quot;Approach to the HIV-infected patient with pulmonary symptoms&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The ocular manifestations of toxoplasmosis can be confused with other infections in HIV, such as retinitis resulting from cytomegalovirus and acute retinal necrosis due to varicella-zoster virus. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-aids-related-cytomegalovirus-retinitis#H14\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis&quot;, section on 'Clinical manifestations'</a> and <a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster#H14\" class=\"medical medical_review\">&quot;Clinical manifestations of varicella-zoster virus infection: Herpes zoster&quot;, section on 'ARN in HIV-infected patients'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of toxoplasmosis in HIV-infected patients includes antimicrobial therapy directed against <em>T. gondii</em>, as well as antiretroviral therapy (ART) for immune recovery. A more detailed discussion on the use of ART is found elsewhere. (See <a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">&quot;Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient&quot;</a> and <a href=\"#H1046537269\" class=\"local\">'When to initiate antiretroviral therapy'</a> below.)</p><p>Antimicrobial therapy targeted against <em>T. gondii</em> involves an initial phase to treat the acute symptoms, followed by maintenance therapy to reduce the risk of recurrence. Extracerebral toxoplasmosis is treated with the same regimens as toxoplasmic encephalitis (TE), although the response may not be as favorable [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/15\" class=\"abstract_t\">15</a>]. For certain patients (eg, those on ART with immune recovery), maintenance therapy can be discontinued. </p><p class=\"headingAnchor\" id=\"H202076538\"><span class=\"h2\">Initial therapy</span></p><p class=\"headingAnchor\" id=\"H202076881\"><span class=\"h3\">Preferred regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We prefer an initial regimen containing <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> and <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>. This regimen is more effective compared with the alternative choices (eg, pyrimethamine plus <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>); however, it is associated with a higher incidence of cutaneous hypersensitivity reactions [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/40\" class=\"abstract_t\">40</a>]. Patients receiving sulfadiazine therapy do <strong>not</strong> require additional <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (TMP-SMX) for prophylaxis against <em>P. jirovecii</em> infections (ie, PCP). (See <a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Overview of prevention of opportunistic infections in HIV-infected patients&quot;</a>.)</p><p>The initial drug regimen is given orally and should be dosed as follows [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,27,40-42\" class=\"abstract_t\">9,27,40-42</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">Sulfadiazine</a> (1000 mg four times daily among patients &lt;60 kg or 1500 mg four times daily among patients &ge;60 kg). If there are concerns about non-adherence, 2000 mg of sulfadiazine can be administered twice daily; one study documented equivalent pharmacokinetic parameters of this dosing schedule compared with 1000 mg given four times a day [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">Pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients &ge;60 kg).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">Leucovorin</a> (10 to 25 mg daily). This agent should be administered to prevent pyrimethamine-induced hematologic toxicity.</p><p/><p>The approach to treatment if <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> is not available and a discussion of patient monitoring on treatment (including potential adverse reactions) are found below. (See <a href=\"#H452467747\" class=\"local\">'If pyrimethamine is not available'</a> below and <a href=\"#H971178678\" class=\"local\">'Monitoring of initial therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h3\">Alternative regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who cannot take <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a>, we administer <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> (600 mg intravenously or orally four times a day) <strong>plus</strong> oral <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients &ge;60 kg) <strong>plus</strong>&nbsp;oral <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 to 25 mg daily). </p><p>For patients without a sulfa allergy, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (TMP-SMX; 5 <span class=\"nowrap\">mg/kg</span> <a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> and 25 <span class=\"nowrap\">mg/kg</span> sulfamethoxazole given intravenously or orally twice daily) may also be an effective alternative treatment regimen [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/44,45\" class=\"abstract_t\">44,45</a>]. This agent may be particularly useful in resource-limited settings given the low cost [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/46\" class=\"abstract_t\">46</a>]. In severely ill patients who cannot take oral therapy, parenteral TMP-SMX should be used for treatment of toxoplasmic encephalitis [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Several other alternatives have been used for patients who are unable to tolerate more commonly used regimens [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/47-50\" class=\"abstract_t\">47-50</a>]. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (1500 mg PO twice daily) <strong>plus </strong><a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients &ge;60 kg) <strong>plus</strong>&nbsp;<a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 to 25 mg PO once daily).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (1500 mg PO twice daily) <strong>plus</strong> <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> (1000 mg PO four times daily among patients &lt;60 kg or 1500 mg PO four times daily among patients &ge;60 kg). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (1500 mg PO twice daily).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">Azithromycin</a> (900 to 1200 mg PO once daily) <strong>plus </strong><a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients &ge;60 kg) <strong>plus</strong>&nbsp;<a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 to 25 mg PO once daily).</p><p/><p>The approach to treatment if <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> is not available and a discussion of patient monitoring on treatment (including potential adverse reactions) are found below. (See <a href=\"#H452467747\" class=\"local\">'If pyrimethamine is not available'</a> below and <a href=\"#H971178678\" class=\"local\">'Monitoring of initial therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H452467747\"><span class=\"h3\">If pyrimethamine is not available</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most of the preferred and alternative regimens for the treatment of toxoplasmosis include <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>. However, as of June 2015 in the United States, access to pyrimethamine is limited and this agent must be obtained through a manufacturer run program or from a compounding pharmacy. Information on how to obtain pyrimethamine can be found at <span class=\"nowrap\">http://www</span>.hivma.<span class=\"nowrap\">org/Pyrimethamine_Alternatives/,</span> and in the Lexicomp drug monograph within UpToDate. </p><p>If <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> cannot be obtained expeditiously, TMP-SMX (in patients without a sulfonamide allergy) or <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a> (in patients with a sulfonamide allergy) should be used until pyrimethamine can be obtained from the manufacturer [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/51\" class=\"abstract_t\">51</a>]. The patient should then be switched to a pyrimethamine-containing regimen. (See <a href=\"#H22\" class=\"local\">'Alternative regimens'</a> above.)</p><p>However, if <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> cannot be obtained, TMP-SMX can be continued. For patients with a sulfonamide allergy, sulfa desensitization should be attempted in those without a history of a severe reaction (eg, Stevens Johnson Syndrome); <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a> should be administered until patients are receiving a therapeutic dose of TMP-SMX [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. More detailed discussions on sulfonamide allergy and desensitization are found elsewhere. (See <a href=\"topic.htm?path=sulfonamide-allergy-in-hiv-uninfected-patients#H10\" class=\"medical medical_review\">&quot;Sulfonamide allergy in HIV-uninfected patients&quot;, section on 'Types of hypersensitivity reactions'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients#H549880787\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis infection in HIV-infected patients&quot;, section on 'Desensitization for patients with a sulfa allergy'</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h3\">Adjunctive therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several therapies that can be administered to help manage the complications of TE. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Corticosteroids &mdash; Adjunctive corticosteroids should only be used for patients with mass effect related to focal brain lesions or edema (eg, individuals with radiographic evidence of midline shift). <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> (4 mg every six hours) is usually chosen and is generally tapered over several days.</p><p/><p class=\"bulletIndent1\">When corticosteroids are used, it may be difficult to assess response to therapy since corticosteroids can result in a rapid improvement in symptoms. Radiographic assessments may also be affected since the corticosteroids will reduce the intensity of ring-enhancement and the amount of surrounding edema. Patients should also be carefully monitored for the development of other opportunistic infections.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticonvulsants &mdash; Anticonvulsants should be administered to patients who present with seizures. They should not be given routinely for prophylaxis to all patients with a presumed diagnosis of TE [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. Careful attention needs to be paid to any potential drug interactions.</p><p/><p class=\"headingAnchor\" id=\"H971178678\"><span class=\"h2\">Monitoring of initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The monitoring of patients with TE includes assessment for adverse drug reactions and clinical improvement, as well as serial brain imaging. There is no value of following IgG toxoplasma antibody titers. (See <a href=\"#H14\" class=\"local\">'Serology'</a> above.)</p><p class=\"headingAnchor\" id=\"H88277034\"><span class=\"h3\">Adverse reactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common side effects of <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> include rash, nausea, and bone marrow suppression. Higher doses of <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a>, (50 mg daily or twice daily), can be administered for management of hematologic abnormalities [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">Sulfadiazine</a> can lead to rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, and crystalluria (leading to renal insufficiency). <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> can also lead to fever, rash, and nausea; its use is also associated with diarrhea related to production of <em>Clostridium difficile</em> toxin.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h3\">Response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with TE, we assess for clinical improvement during the first two weeks of therapy. Clinical improvement usually precedes radiographic improvement. Thus, careful daily neurologic examinations are more important than radiographic studies in assessing the initial response to therapy. </p><p>We perform neuroimaging after two to three weeks of treatment, or sooner if the patient has not demonstrated clinical improvement within the first week or has shown any worsening. Lack of clinical <span class=\"nowrap\">and/or</span> radiographic improvement within 10 to 14 days of starting empiric therapy for TE should raise the possibility of an alternative diagnosis. Brain biopsy should be considered in such patients. (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p>Approximately 75 to 80 percent of patients treated for TE demonstrate clinical and radiologic improvement [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/27,49\" class=\"abstract_t\">27,49</a>]. As an example, in a study of 49 patients treated for TE with <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> plus <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, 35 (71 percent) responded overall with the vast majority demonstrating &ge;50 percent improvement in their baseline abnormalities by day 14 of therapy [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/27\" class=\"abstract_t\">27</a>]. However, the literature dealing with response to therapy is hampered by presumptive diagnoses, cross-over treatments, and discontinuation for toxicity, rather than lack of clinical response.</p><p class=\"headingAnchor\" id=\"H971178726\"><span class=\"h2\">Duration of initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who respond to treatment, the duration of initial therapy is typically six weeks at the doses recommended above (see <a href=\"#H202076538\" class=\"local\">'Initial therapy'</a> above). Following that, it is usually safe to administer lower doses for chronic maintenance therapy (also referred to as secondary prophylaxis). (See <a href=\"#H202076667\" class=\"local\">'Maintenance therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Special considerations during pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pregnant women who acquire toxoplasmosis during pregnancy should be managed in conjunction with a maternal-fetal medicine specialist. A detailed discussion on the diagnosis and management of pregnant women with primary toxoplasmosis infection is found elsewhere. (See <a href=\"topic.htm?path=toxoplasmosis-and-pregnancy\" class=\"medical medical_review\">&quot;Toxoplasmosis and pregnancy&quot;</a>.)</p><p>HIV infected patients who become pregnant are typically managed by a maternal-fetal medicine specialist in conjunction with an infectious disease specialist. The approach to treatment of such women who develop reactivation disease (eg, TE or extracerebral toxoplasmosis) should be the same as in the nonpregnant adult [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. Although <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> has been associated with birth defects in animals, limited human data have not suggested an increased risk for defects [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,52\" class=\"abstract_t\">9,52</a>]. In addition, ultrasound examination of the fetus should be performed to assess for evidence of congenital infection (eg, hydrocephalus, cerebral calcifications, and growth restriction) [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. There have been case reports of <em>T. gondii</em> transmission from HIV-infected women with significant immunosuppression and symptomatic reactivation disease to their fetus [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/53\" class=\"abstract_t\">53</a>]. Congenital transmission of <em>T. gondii</em> among asymptomatic HIV-infected women who are not immunosuppressed has not been reported [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/54-56\" class=\"abstract_t\">54-56</a>]. </p><p class=\"headingAnchor\" id=\"H202076667\"><span class=\"h2\">Maintenance therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We transition most patients to maintenance therapy after six weeks of treatment with the initial regimen. This includes both patients with TE and extracerebral disease. The goal of maintenance therapy (also referred to as secondary prophylaxis) is to prevent relapse of infection. For patients with TE, we perform neuroimaging prior to this transition to establish a new baseline. This information can be useful if there is concern for relapse or an immune reconstitution inflammatory syndrome (IRIS). (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H202076869\"><span class=\"h3\">Regimens for maintenance therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For maintenance therapy, a combination of <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> and <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> should be continued, but at lower doses than those used for initial treatment. We follow guidelines that suggest sulfadiazine be administered as 2000 to 4000 mg daily in two to four divided doses with pyrimethamine 25 to 50 mg daily and <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> 10 to 25 mg daily [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. We favor twice-daily dosing of sulfadiazine for patient convenience, and&nbsp;typically administer 1000 mg twice daily for individuals &lt;60 kg, and 1500 mg twice daily for individuals &ge;60 kg. </p><p>Other alternative oral regimens include [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> (600 mg every eight hours) plus <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (25 to 50 mg daily) plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 to 25 mg daily) [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,40\" class=\"abstract_t\">9,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a> one double strength tablet twice daily [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/44,57\" class=\"abstract_t\">44,57</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (750 to 1500 mg twice daily) with <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (25 mg daily) plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 mg daily) [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,48,58\" class=\"abstract_t\">9,48,58</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (750 to 1500 mg twice daily) with <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> (2000 to 4000 mg daily in two to four divided doses). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> monotherapy (750 to 1500 mg twice daily) can be administered to patients who cannot tolerate <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>, but the one-year relapse rate may be higher (26 percent) [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"headingAnchor\" id=\"H202076360\"><span class=\"h3\">Discontinuing maintenance therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic maintenance therapy (ie, secondary prophylaxis) for TE can be discontinued in asymptomatic patients who have completed initial therapy if they are receiving antiretroviral therapy (ART), have a suppressed HIV viral load, and have maintained a CD4 count &gt;200 <span class=\"nowrap\">cells/microL</span> for at least six months [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]. Various studies show that immune responses against <em>T. gondii</em> are restored in such patients [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/59,60\" class=\"abstract_t\">59,60</a>]. Patients who stop maintenance therapy should be educated to seek medical attention for recurrent symptoms since relapses have been reported [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/59,61-64\" class=\"abstract_t\">59,61-64</a>]. Maintenance therapy should be reinitiated if the CD4 cell count declines to &lt;200 <span class=\"nowrap\">cells/microL</span>. A discussion of when to initiate ART is found below. (See <a href=\"#H1046537269\" class=\"local\">'When to initiate antiretroviral therapy'</a> below.)</p><p>We do <strong>not</strong> use neuroimaging to guide our decision about when to stop secondary prophylaxis. We repeat neuroimaging after induction therapy to get a post-treatment baseline and monitor patients clinically for relapse. However, some experts obtain magnetic resonance imaging of the brain to decide if it is safe to stop maintenance therapy, and they base their decision upon the presence of residual disease.</p><p class=\"headingAnchor\" id=\"H10923597\"><span class=\"h1\">TOXOPLASMOSIS AND IMMUNE RECONSTITUTION SYNDROME (IRIS)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;immune reconstitution inflammatory syndrome&quot; (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of pre-existing infectious processes following the initiation of potent antiretroviral therapy (ART) in HIV-infected individuals [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/65-70\" class=\"abstract_t\">65-70</a>]. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p>IRIS can complicate central nervous system (CNS) infections, as has been well described for mycobacteria and cryptococcal infections. However, fewer cases of IRIS related to CNS toxoplasmosis have been reported [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/71,72\" class=\"abstract_t\">71,72</a>]. IRIS in association with toxoplasmosis can lead to a paradoxical worsening of symptoms with worsening edema surrounding brain lesions as CD4 cell counts rapidly improve [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/72\" class=\"abstract_t\">72</a>]. Management includes continuing treatment for toxoplasmic encephalitis (TE) and antiretroviral treatment for HIV, and increasing the dose of steroids, as needed, to control symptoms. If the diagnosis of IRIS is unclear, a biopsy may be needed to rule out an alternative process, such as lymphoma [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/72\" class=\"abstract_t\">72</a>].</p><p>In patients without a prior diagnosis of TE, IRIS can present as an &quot;unmasking&quot; of an infection that previously existed, but was not diagnosed until the onset of immune recovery. In one case series of 65 patients with TE, three were diagnosed with CNS disease only after the initiation of ART [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/73\" class=\"abstract_t\">73</a>]. In such patients, symptoms occurred at a median time of 41 days after starting antiretroviral therapy and at a median CD4 count of 222 <span class=\"nowrap\">cells/microL</span>.</p><p class=\"headingAnchor\" id=\"H1046537269\"><span class=\"h1\">WHEN TO INITIATE ANTIRETROVIRAL THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with toxoplasmosis are not receiving antiretroviral therapy (ART) at the time of diagnosis. We initiate ART within two weeks of starting treatment for toxoplasmosis, typically as soon as it is clear that the patient is tolerating toxoplasmosis therapy. Although there are no definitive studies on the optimal time to initiate antiretroviral therapy in patients with toxoplasmosis, the benefits of early ART (eg, reduced disease progression and death) have been demonstrated in patients with a variety of opportunistic infections, including some with toxoplasmosis [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,74\" class=\"abstract_t\">9,74</a>].</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For HIV-infected patients, the risk of developing toxoplasmosis can be reduced by avoiding exposure to the pathogen or by using prophylactic antibiotics to decrease the risk of reactivation. All HIV-infected patients should be tested for prior exposure to <em>T. gondii</em> by measuring anti-toxoplasma IgG, ideally when first diagnosed with HIV [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/75\" class=\"abstract_t\">75</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients <strong>without</strong> evidence of prior infection with toxoplasmosis, initial infection can be prevented by taking certain precautions. This is discussed in detail elsewhere. (See <a href=\"topic.htm?path=toxoplasmosis-in-immunocompetent-hosts#H210691\" class=\"medical medical_review\">&quot;Toxoplasmosis in immunocompetent hosts&quot;, section on 'Prevention'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For individuals <strong>with</strong> evidence of prior toxoplasmosis (ie, those with a positive serology), antimicrobial therapy can decrease the risk of developing reactivation disease. This is referred to as primary prophylaxis and is described below.</p><p/><p class=\"headingAnchor\" id=\"H30\"><span class=\"h2\">Primary prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary prophylaxis is indicated for patients with HIV and CD4 counts &lt;100 <span class=\"nowrap\">cells/microL</span> who are <em>T. gondii</em> IgG-positive. Most data on the efficacy of primary prophylaxis for toxoplasmosis come from retrospective analyses of trials evaluating antimicrobial treatment to prevent Pneumocystis infection [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/76-79\" class=\"abstract_t\">76-79</a>]. The risk of developing toxoplasmic encephalitis (TE) for patients with AIDS who are using primary prophylaxis is 0 to 2.4 percent for TMP-SMX and 0 to 11 percent for dapsone-pyrimethamine [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/80\" class=\"abstract_t\">80</a>]. <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> for primary prophylaxis of toxoplasmosis has not been studied, and the recommendation for its use as an alternate agent for primary prophylaxis is based upon its efficacy in the treatment of TE. (See <a href=\"#H22\" class=\"local\">'Alternative regimens'</a> above.)</p><p>We administer <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (TMP-SMX) as primary prophylaxis against reactivation. We administer one double strength (DS) tablet (800 <span class=\"nowrap\">mg/160</span> mg) per day. However, for patients unable to tolerate this dose, TMP-SMX can be given as one DS tablet three times per week or one single strength tablet (400 <span class=\"nowrap\">mg/80</span> mg) daily. If the patient cannot take TMP-SMX, we use one of the following oral regimens [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> (50 mg once daily) plus <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (50 mg per week) plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (25 mg per week) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> (200 mg per week) plus <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (75 mg per week) plus <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (25 mg per week) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> (1500 mg once daily) with or without <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> (25 mg once daily); if pyrimethamine is given, <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (10 mg daily) should also be used</p><p/><p>Monotherapy with <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>, <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, or <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> is <strong>not</strong> recommended.</p><p>For pregnant women who have a CD4 cell count &lt;100 <span class=\"nowrap\">cells/microL,</span> the benefit of prophylaxis must be weighed against the risk to the fetus. The specific risks depend upon the type of prophylaxis used. A discussion on the risk of TMP-SMX during pregnancy is found elsewhere. (See <a href=\"topic.htm?path=prenatal-evaluation-of-the-hiv-infected-woman-in-resource-rich-settings#H8632859\" class=\"medical medical_review\">&quot;Prenatal evaluation of the HIV-infected woman in resource-rich settings&quot;, section on 'Chemoprophylaxis for opportunistic infections'</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h2\">Discontinuation of primary prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving antiretroviral therapy can safely discontinue primary prophylaxis for toxoplasmosis if their HIV viral load is suppressed and their CD4 count is &gt;200 <span class=\"nowrap\">cells/microL</span> for at least three months [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9,81,82\" class=\"abstract_t\">9,81,82</a>]. This is supported by a study of 199 patients who discontinued primary prophylaxis for toxoplasmosis after having a sustained increase in their CD4 count (&gt;200 <span class=\"nowrap\">cells/microL)</span> for &gt;12 weeks while receiving ART [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/81\" class=\"abstract_t\">81</a>]. None of the patients developed toxoplasmic encephalitis during a follow-up of 272 person-years. Prophylaxis should be reinstated if the CD4 count drops to &lt;200 <span class=\"nowrap\">cells/microL</span> [<a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H2244368820\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The probability of developing reactivated toxoplasmosis is as high as 30 percent among AIDS patients with a CD4 count &lt;100 <span class=\"nowrap\">cells/microL</span> who are toxoplasma seropositive and are not receiving effective prophylaxis or antiretroviral therapy. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reactivation of toxoplasmosis most frequently presents with signs and symptoms of central nervous system disease in HIV-infected patients with a CD4 count &lt;100 <span class=\"nowrap\">cells/microL</span>. Extracerebral disease can also occur and may be present at more than one site. (See <a href=\"#H6\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the majority of patients, therapy is initiated after making a presumptive, rather than definitive, diagnosis of toxoplasmic encephalitis (TE). (See <a href=\"#H13\" class=\"local\">'Approach to diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A presumptive diagnosis of TE can be made if the patient has a CD4 count &lt;100 <span class=\"nowrap\">cells/microL,</span> has not been receiving effective prophylaxis for toxoplasma, and has all of the following (see <a href=\"#H13\" class=\"local\">'Approach to diagnosis'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A compatible clinical syndrome (see <a href=\"#H7\" class=\"local\">'Toxoplasmic encephalitis'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A positive <em>T. gondii</em> IgG antibody (see <a href=\"#H14\" class=\"local\">'Serology'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Brain imaging (preferably magnetic resonance imaging) that demonstrates a typical radiographic appearance (eg, multiple ring-enhancing lesions) (see <a href=\"#H15\" class=\"local\">'Imaging'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of TE includes central nervous system (CNS) lymphoma, tuberculoma, cryptococcoma, bacterial abscess, and uncommonly, progressive multifocal leukoencephalopathy. (See <a href=\"#H20\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment of toxoplasmosis in HIV-infected patients includes antimicrobial therapy directed against <em>T. gondii</em>, as well as antiretroviral therapy (ART) for immune recovery. (See <a href=\"#H21\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We prefer an initial regimen containing <a href=\"topic.htm?path=sulfadiazine-drug-information\" class=\"drug drug_general\">sulfadiazine</a> and <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>. This regimen is more effective compared with the alternative choices (eg, pyrimethamine plus <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>); however, it is associated with a higher incidence of cutaneous hypersensitivity reactions. (See <a href=\"#H202076538\" class=\"local\">'Initial therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who respond to treatment, the duration of initial therapy is typically six weeks at the doses recommended above. Following that, it is usually safe to administer lower doses for chronic maintenance therapy. (See <a href=\"#H971178726\" class=\"local\">'Duration of initial therapy'</a> above and <a href=\"#H202076667\" class=\"local\">'Maintenance therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients with toxoplasmosis are not on antiretroviral therapy (ART) at the time of diagnosis. We initiate ART within two weeks of starting treatment for toxoplasmosis, typically as soon as it is clear that the patient is tolerating toxoplasmosis therapy. (See <a href=\"#H1046537269\" class=\"local\">'When to initiate antiretroviral therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For HIV-infected patients, the risk of developing toxoplasmosis can be reduced by avoiding exposure to the pathogen or by using prophylactic antibiotics to decrease the risk of reactivation. (See <a href=\"#H29\" class=\"local\">'Prevention'</a> above.)</p><p/><p><strong>ACKNOWLEDGMENT</strong> &mdash; The editorial staff at UpToDate would like to acknowledge Howard Heller, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/1\" class=\"nounderline abstract_t\">Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/2\" class=\"nounderline abstract_t\">San-Andr&eacute;s FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003; 36:1177.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/3\" class=\"nounderline abstract_t\">Renold C, Sugar A, Chave JP, et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) 1992; 71:224.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/4\" class=\"nounderline abstract_t\">Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/5\" class=\"nounderline abstract_t\">Grant IH, Gold JW, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990; 4:519.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/6\" class=\"nounderline abstract_t\">Blaser MJ, Cohn DL. Opportunistic infections in patients with AIDS: clues to the epidemiology of AIDS and the relative virulence of pathogens. Rev Infect Dis 1986; 8:21.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/7\" class=\"nounderline abstract_t\">Leport C, Ch&ecirc;ne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 1996; 173:91.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/8\" class=\"nounderline abstract_t\">Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33:1747.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on August 08, 2017).</li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/10\" class=\"nounderline abstract_t\">Falusi O, French AL, Seaberg EC, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002; 35:1414.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/11\" class=\"nounderline abstract_t\">Wallace MR, Rossetti RJ, Olson PE. Cats and toxoplasmosis risk in HIV-infected adults. JAMA 1993; 269:76.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/12\" class=\"nounderline abstract_t\">Levy RM, Janssen RS, Bush TJ, Rosenblum ML. Neuroepidemiology of acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988; 1:31.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/13\" class=\"nounderline abstract_t\">Jones JL, Roberts JM. Toxoplasmosis hospitalizations in the United States, 2008, and trends, 1993-2008. Clin Infect Dis 2012; 54:e58.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/14\" class=\"nounderline abstract_t\">Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 1999; 28:575.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/15\" class=\"nounderline abstract_t\">Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73:306.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/16\" class=\"nounderline abstract_t\">Pugin J, Vanhems P, Hirschel B, et al. Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med 1992; 326:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/17\" class=\"nounderline abstract_t\">Butt AA, Michaels S, Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002; 6:178.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/18\" class=\"nounderline abstract_t\">Rabaud C, May T, Lucet JC, et al. Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. Clin Infect Dis 1996; 23:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/19\" class=\"nounderline abstract_t\">Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology 2004; 111:716.</a></li><li class=\"breakAll\">Montoya JG, Remington JS. Toxoplasma gondii. In: Principles and Practice of Infectious Diseases, 5th Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.2858.</li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/21\" class=\"nounderline abstract_t\">Vyas R, Ebright JR. Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Clin Infect Dis 1996; 23:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/22\" class=\"nounderline abstract_t\">Lucet JC, Bailly MP, Bedos JP, et al. Septic shock due to toxoplasmosis in patients infected with the human immunodeficiency virus. Chest 1993; 104:1054.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/23\" class=\"nounderline abstract_t\">Hofman P, Bernard E, Michiels JF, et al. Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS). Pathol Res Pract 1993; 189:894.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/24\" class=\"nounderline abstract_t\">Cohn JA, McMeeking A, Cohen W, et al. Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med 1989; 86:521.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/25\" class=\"nounderline abstract_t\">Andrews BT, Kenefick TP. Neurosurgical management of the acquired immunodeficiency syndrome. An update. West J Med 1993; 158:249.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/26\" class=\"nounderline abstract_t\">Luft BJ, Brooks RG, Conley FK, et al. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 1984; 252:913.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/27\" class=\"nounderline abstract_t\">Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993; 329:995.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/28\" class=\"nounderline abstract_t\">Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr 1990; 3:461.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/29\" class=\"nounderline abstract_t\">Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990; 73:720.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/30\" class=\"nounderline abstract_t\">Miller RF, Hall-Craggs MA, Costa DC, et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect 1998; 74:258.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/31\" class=\"nounderline abstract_t\">Skiest DJ, Erdman W, Chang WE, et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40:274.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/32\" class=\"nounderline abstract_t\">Westwood TD, Hogan C, Julyan PJ, et al. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 2013; 82:e374.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/33\" class=\"nounderline abstract_t\">Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39:1366.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/34\" class=\"nounderline abstract_t\">O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/35\" class=\"nounderline abstract_t\">Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12:690.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/36\" class=\"nounderline abstract_t\">Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48:687.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/37\" class=\"nounderline abstract_t\">Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11:1.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/38\" class=\"nounderline abstract_t\">Nogui FL, Mattas S, Turcato J&uacute;nior G, Lewi DS. Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. Braz J Infect Dis 2009; 13:18.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/39\" class=\"nounderline abstract_t\">Mesquita RT, Ziegler AP, Hiramoto RM, et al. Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. J Med Microbiol 2010; 59:641.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/40\" class=\"nounderline abstract_t\">Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/41\" class=\"nounderline abstract_t\">Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/42\" class=\"nounderline abstract_t\">Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003; 5:3.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/43\" class=\"nounderline abstract_t\">Jordan MK, Burstein AH, Rock-Kress D, et al. Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:635.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/44\" class=\"nounderline abstract_t\">Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother 1998; 42:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/45\" class=\"nounderline abstract_t\">B&eacute;raud G, Pierre-Fran&ccedil;ois S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg 2009; 80:583.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/46\" class=\"nounderline abstract_t\">Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006; :CD005420.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/47\" class=\"nounderline abstract_t\">Jacobson JM, Hafner R, Remington J, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001; 15:583.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/48\" class=\"nounderline abstract_t\">Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997; 24:422.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/49\" class=\"nounderline abstract_t\">Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/50\" class=\"nounderline abstract_t\">Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992; 340:637.</a></li><li class=\"breakAll\">Department of Health and Human Services. Notice of availability of pyrimethamine. https://aidsinfo.nih.gov/news/1604/notice-of-availability-of-pyrimethamine (Accessed on September 16, 2015).</li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/52\" class=\"nounderline abstract_t\">Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001; 95:424.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/53\" class=\"nounderline abstract_t\">Bachmeyer C, Mouchnino G, Thulliez P, Blum L. Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation. J Infect 2006; 52:e55.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/54\" class=\"nounderline abstract_t\">Lago EG, Conrado GS, Piccoli CS, et al. Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009; 28:345.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/55\" class=\"nounderline abstract_t\">Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996; 68:93.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/56\" class=\"nounderline abstract_t\">Minkoff H, Remington JS, Holman S, et al. Vertical transmission of toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol 1997; 176:555.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/57\" class=\"nounderline abstract_t\">Duval X, Pajot O, Le Moing V, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS 2004; 18:1342.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/58\" class=\"nounderline abstract_t\">Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS 1996; 10:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/59\" class=\"nounderline abstract_t\">Lejeune M, Mir&oacute; JM, De Lazzari E, et al. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clin Infect Dis 2011; 52:662.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/60\" class=\"nounderline abstract_t\">Furco A, Carmagnat M, Chevret S, et al. Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS 2008; 22:2087.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/61\" class=\"nounderline abstract_t\">Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000; 30:602.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/62\" class=\"nounderline abstract_t\">Soriano V, Dona C, Rodr&iacute;guez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/63\" class=\"nounderline abstract_t\">Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/64\" class=\"nounderline abstract_t\">Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/65\" class=\"nounderline abstract_t\">DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/66\" class=\"nounderline abstract_t\">French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/67\" class=\"nounderline abstract_t\">Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/68\" class=\"nounderline abstract_t\">Michelet C, Arvieux C, Fran&ccedil;ois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/69\" class=\"nounderline abstract_t\">Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/70\" class=\"nounderline abstract_t\">Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/71\" class=\"nounderline abstract_t\">Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20:482.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/72\" class=\"nounderline abstract_t\">Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis. Ann Intern Med 2009; 150:656.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/73\" class=\"nounderline abstract_t\">Martin-Blondel G, Alvarez M, Delobel P, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:691.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/74\" class=\"nounderline abstract_t\">Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/75\" class=\"nounderline abstract_t\">Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/76\" class=\"nounderline abstract_t\">Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/77\" class=\"nounderline abstract_t\">Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/78\" class=\"nounderline abstract_t\">Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995; 9:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/79\" class=\"nounderline abstract_t\">Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:104.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/80\" class=\"nounderline abstract_t\">Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120:932.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/81\" class=\"nounderline abstract_t\">Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217.</a></li><li><a href=\"https://www.uptodate.com/contents/toxoplasmosis-in-hiv-infected-patients/abstract/82\" class=\"nounderline abstract_t\">Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3710 Version 25.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H33\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H878458677\" id=\"outline-link-H878458677\">Transmission</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Prevalence of infection</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Toxoplasmic encephalitis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Extracerebral toxoplasmosis</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Pneumonitis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Chorioretinitis</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Other manifestations</a></li></ul></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">DIAGNOSIS</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Approach to diagnosis</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Serology</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Imaging</a></li><li><a href=\"#H45189708\" id=\"outline-link-H45189708\">Occasionally performed tests</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">- Nuclear imaging</a></li><li><a href=\"#H824493468\" id=\"outline-link-H824493468\">- Visualization of the organism</a></li><li><a href=\"#H878459301\" id=\"outline-link-H878459301\">- Polymerase chain reaction</a></li></ul></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H382302669\" id=\"outline-link-H382302669\">Central nervous system disease</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">TREATMENT</a><ul><li><a href=\"#H202076538\" id=\"outline-link-H202076538\">Initial therapy</a><ul><li><a href=\"#H202076881\" id=\"outline-link-H202076881\">- Preferred regimens</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">- Alternative regimens</a></li><li><a href=\"#H452467747\" id=\"outline-link-H452467747\">- If pyrimethamine is not available</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">- Adjunctive therapies</a></li></ul></li><li><a href=\"#H971178678\" id=\"outline-link-H971178678\">Monitoring of initial therapy</a><ul><li><a href=\"#H88277034\" id=\"outline-link-H88277034\">- Adverse reactions</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">- Response to therapy</a></li></ul></li><li><a href=\"#H971178726\" id=\"outline-link-H971178726\">Duration of initial therapy</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Special considerations during pregnancy</a></li><li><a href=\"#H202076667\" id=\"outline-link-H202076667\">Maintenance therapy</a><ul><li><a href=\"#H202076869\" id=\"outline-link-H202076869\">- Regimens for maintenance therapy</a></li><li><a href=\"#H202076360\" id=\"outline-link-H202076360\">- Discontinuing maintenance therapy</a></li></ul></li></ul></li><li><a href=\"#H10923597\" id=\"outline-link-H10923597\">TOXOPLASMOSIS AND IMMUNE RECONSTITUTION SYNDROME (IRIS)</a></li><li><a href=\"#H1046537269\" id=\"outline-link-H1046537269\">WHEN TO INITIATE ANTIRETROVIRAL THERAPY</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">PREVENTION</a><ul><li><a href=\"#H30\" id=\"outline-link-H30\">Primary prophylaxis</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">Discontinuation of primary prophylaxis</a></li></ul></li><li><a href=\"#H2244368820\" id=\"outline-link-H2244368820\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H33\" id=\"outline-link-H33\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/3710|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ID/50593\" class=\"graphic graphic_algorithm\">- Management of HIV patients with CNS lesions algorithm</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">Approach to HIV-infected patients with central nervous system lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-hiv-infected-patient-with-pulmonary-symptoms\" class=\"medical medical_review\">Approach to the HIV-infected patient with pulmonary symptoms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">Clinical manifestations of varicella-zoster virus infection: Herpes zoster</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Overview of prevention of opportunistic infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-aids-related-cytomegalovirus-retinitis\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prenatal-evaluation-of-the-hiv-infected-woman-in-resource-rich-settings\" class=\"medical medical_review\">Prenatal evaluation of the HIV-infected woman in resource-rich settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selecting-antiretroviral-regimens-for-the-treatment-naive-hiv-infected-patient\" class=\"medical medical_review\">Selecting antiretroviral regimens for the treatment-na&iuml;ve HIV-infected patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sulfonamide-allergy-in-hiv-uninfected-patients\" class=\"medical medical_review\">Sulfonamide allergy in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-natural-history-and-clinical-features-of-hiv-infection-in-adults-and-adolescents\" class=\"medical medical_review\">The natural history and clinical features of HIV infection in adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasma-pneumonia-and-other-parasitic-pulmonary-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Toxoplasma pneumonia and other parasitic pulmonary infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasmosis-and-pregnancy\" class=\"medical medical_review\">Toxoplasmosis and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasmosis-in-immunocompetent-hosts\" class=\"medical medical_review\">Toxoplasmosis in immunocompetent hosts</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment and prevention of Pneumocystis infection in HIV-infected patients</a></li></ul></div></div>","javascript":null}